Background Venous thromboembolism (VTE) is a common cause of morbidity and mortality
among patients with cancer. As such, we conducted a meta-analysis of randomized …

Purpose To develop guideline recommendations for the use of anticoagulation in the
prevention and treatment of venous thromboembolism (VTE) in patients with cancer …

PURPOSE To provide updated recommendations about prophylaxis and treatment of
venous thromboembolism (VTE) in patients with cancer. METHODS PubMed and the …

Cancer patients in general have a high risk of venous thromboembolic events (VTE) driven
not only by patient-related risk factors, but also risk factors related to the disease and anti …

Background Venous thromboembolism (VTE) is a leading cause of morbidity and mortality in
patients with cancer. Expert consensus recommends a risk‐based approach to guide …

Abstract Background Venous thromboembolism (Wickham et al., 2012 [1]) is a leading
cause of morbidity and mortality among patients with cancer; however, primary …

Patients with cancer are at increased risk of venous thromboembolism (vte). Anticoagulation
therapy has been shown to prevent vte; however, unique clinical circumstances in patients …

In the general population, the incidence of thromboembolic events is 117 cases/100,000
inhabitants/year, while in cancer patient incidence, it is four-fold higher, especially in …

Purpose To provide recommendations about prophylaxis and treatment of venous
thromboembolism (VTE) in patients with cancer. Prophylaxis in the outpatient, inpatient, and …

Cancer is a highly thrombophilic entity leading to a high rate of symptomatic and even
asymptomatic venous thromboembolic (VTE) events in patients suffering from malignant …